Protective effects of testosterone replacement therapy on brain tumor outcomes: The Mayo Clinic experience.

Authors

Manuel M Bettencourt, Shreya Gandhi, Archis Bhandarkar, Asad Lone, Gelareh Zadeh, Sheila Mansouri

Published in

Neuro-oncology advances. Volume 8. Issue 1. Pages vdag259. Epub Oct 07, 2026.

Abstract

Biological sex and endocrine signaling influence cancer biology, immune response, and therapeutic outcomes. Recent evidence suggests that testosterone signaling may exert brain-context-dependent protective effects in glioblastoma (GBM) through the hypothalamic-pituitary-adrenal axis, reduced glucocorticoid-mediated immune suppression, and altered tumor-immune interactions. We assessed whether testosterone replacement therapy (TRT) exposure was associated with survival in solid tumor central nervous system (CNS) metastases and glioblastoma (GBM, IDH-wildtype, WHO grade 4), settings in which post-diagnosis survival and TRT timing can be clinically defined.
We performed a retrospective Mayo Clinic cohort study of adult patients with molecularly confirmed GBM and solid tumor CNS metastases confirmed from neuroimaging reports using large language model-assisted adjudication. TRT exposure was defined by testosterone-specific prescription evidence within prespecified peri-diagnostic windows. Overall survival was evaluated using propensity score-matched Cox models, 24-month administratively censored Cox models, time-dependent Cox sensitivity analyses, and 24-month restricted mean survival time.
In the pooled solid tumor CNS metastasis cohort, TRT exposure was associated with improved overall survival after propensity score matching (HR 0.80, 95% CI, 0.65-0.98, P = .029) and a 3.22-month improvement in 24-month restricted mean survival time. In GBM, TRT exposure was similarly associated with improved overall survival after propensity score matching (HR 0.38, 95% CI, 0.14-0.98, P = .046) and a 5.81-month improvement in 24-month restricted mean survival time.
TRT exposure was associated with improved survival in CNS metastases and glioblastoma. These hypothesis-generating findings support prospective studies incorporating TRT timing, hormone levels, corticosteroid exposure, immune correlates, and tumor-specific stratification.

PMID:
42927412
Bibliographic data and abstract were imported from PubMed on 25 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.